While approximately half of all ET and primary myelofibrosis (PMF) patients harbour the JAK2 V617F mutation, a further subset has evidence of somatic, activating, MPL (myeloproliferative leukemia virus oncogene) exon 10 mutations that are more frequently found in PMF than ET. Here, MPL is linked to primary myelofibrosis.